MYGN:NASDAQMyriad Genetics, Inc. Analysis

Myriad Genetics sits at a price that is well below its 30‑day and 90‑day moving averages (4.63 $ vs. SMA‑20 = 4.11 $ and SMA‑50 = 4.45 $) and near 0.4× its annual sales, indicating a very low valuation relative to revenue.
The technical picture is mixed: a bullish MACD (positive line, negative signal, positive histogram) and a modest RSI of 57.5 suggest short‑term upside, yet the overall trend is flagged as "bearish" and the 30‑day volatility sits at an extreme 87 %, while a high beta of ~1.6 points to strong market sensitivity. Financially, the company is challenged – revenue fell 20 % YoY, operating and profit margins are negative, cash flow is negative and the forward P/E (30.6×) exceeds the industry average (24.9×). However, recent news highlights a robust 2026 oncology launch pipeline (new Prolaris + AI test, expanded cancer‑care continuum) that could lift the stock and justify a sizable upside of ~35 % (target median 5.75 $).